Applied DNA Sciences Inc
NASDAQ:APDN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Applied DNA Sciences Inc
NASDAQ:APDN
|
US |
|
Mercuria Holdings Co Ltd
TSE:7347
|
JP |
|
Fukuoka REIT Corp
TSE:8968
|
JP |
|
T
|
TravelSky Technology Ltd
HKEX:696
|
CN |
|
A
|
Abercrombie & Fitch Co
LSE:0R32
|
US |
|
CK Infrastructure Holdings Ltd
HKEX:1038
|
HK |
|
R
|
Reservoir Media Inc
F:0RL0
|
US |
|
Kimberly-Clark de Mexico SAB de CV
BMV:KIMBERA
|
MX |
|
Santos Ltd
ASX:STO
|
AU |
|
R
|
Refinverse Group Inc
TSE:7375
|
JP |
|
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
KR |
|
Hualan Biological Engineering Inc
SZSE:002007
|
CN |
Applied DNA Sciences Inc
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Strategic Restructuring: Applied DNA exited its DNA tagging and Security Products business and cut workforce by 20% to focus on its LineaRx synthetic DNA manufacturing.
Revenue Growth: Q1 fiscal 2025 revenue rose to $1.2 million from $891,000 last year, driven by higher product and testing revenues.
Improved Operating Loss: Operating loss narrowed to $3 million from $3.8 million, mainly due to lower SG&A expenses.
LineaRx Focus: Management highlighted strong demand and customer engagement for LineaRx platforms, with over 25 active projects and GMP facility now online.
New Product Launch: The company launched "Linea donor DNA" for CRISPR gene editing and plans to expand GMP capabilities for new DNA products.
Financial Position: Cash and equivalents were $9.3 million as of December 31 and $8.2 million as of January 31; company continues to face going concern risks.
Growth Strategy: Company aims for growth and profitability through modular, low-CapEx DNA manufacturing and disciplined cost management.
